DAD Trial
Double Antibody–Drug Conjugate (DAD): Phase I Trial of Sacituzumab Govitecan + Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Released: October 26, 2023

Activity

Progress
1
Course Completed